title: Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer's disease.
abstract: OBJECTIVE
  SuHeXiang Wan (SHXW) is a Chinese traditional medicinal prescription that consists of 15 crude herbs. SHXW has been used to treat central nervous depression, seizures, infantile convulsion and stroke, and its essential oil has been shown to have anticonvulsant and antioxidative activity. The goal of this study was to investigate the beneficial effects of SHXW on the neurological phenotypes of Drosophila AD models.
  
  
  METHODS
  We evaluated the effects of a modified SHXW (called KSOP1009) intake on the AD-like phenotypes of Drosophila AD models, which express human Aβ42 in their developing eyes or neurons.
  
  
  RESULTS
  When the flies were kept on the media containing 5 μg/ml of KSOP1009 extract, Aβ42-induced eye degeneration, apoptosis, and the locomotive dysfunctions were strongly suppressed. However, Aβ42 fibril deposits in the Aβ42 overexpressing model were not affected by treatment with KSOP1009 extract. Conversely, KSOP1009 extract intake significantly suppressed the constitutive active form of hemipterous, a JNK activator, while it induced eye degeneration and JNK activation, which has been recognized as an important mediator of Aβ42-associated neuro-cytotoxicity.
  
  
  CONCLUSIONS
  In conclusion, the results of this study suggest that KSOP1009 confers a therapeutic potential to AD-like pathology of Aβ42 overexpressing Drosophila model via suppression of the hyperactivation of JNK activity and apoptosis.
authors.affiliation: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea.
authors.forename: Yoon Ki
authors.initials: YK
authors.lastname: Hong
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Park
authors.forename: Soojin
authors.initials: S
authors.lastname: Lee
authors.forename: Soojin
authors.initials: S
authors.lastname: Hwang
authors.forename: Min Jung
authors.initials: MJ
authors.lastname: Lee
authors.forename: Darae
authors.initials: D
authors.lastname: Kim
authors.forename: Jang Ho
authors.initials: JH
authors.lastname: Lee
authors.forename: Seung Yeop
authors.initials: SY
authors.lastname: Han
authors.forename: Sang Tae
authors.initials: ST
authors.lastname: Kim
authors.forename: Young-Kyoon
authors.initials: YK
authors.lastname: Kim
authors.forename: Songhee
authors.initials: S
authors.lastname: Jeon
authors.forename: Byung-Soo
authors.initials: BS
authors.lastname: Koo
authors.forename: Kyoung Sang
authors.initials: KS
authors.lastname: Cho
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D000818:Animals; D017209:Apoptosis; D004195:Disease Models, Animal; D004330:Drosophila; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D048670:MAP Kinase Kinase 4 / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use*
chemical_list: D004365:Drugs, Chinese Herbal; D018696:Neuroprotective Agents; C560536:SuHeXiang Wan; D048670:MAP Kinase Kinase 4